Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure

References

• Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409–436. doi: 10.3322/caac.21731
   PubMed Web of Science ®Google Scholar
• Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40(6):611–625. doi: 10.1200/JCO.21.01626
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. doi: 10.1038/nature05945
   PubMed Web of Science ®Google Scholar
• Liu S, Huang T, Liu M, et al. The genomic characteristics of ALK fusion positive Tumors in Chinese NSCLC patients. Front Oncol. 2020;10:726. doi: 10.3389/fonc.2020.00726
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Tin Tin S, Khwaounjoo P, et al. Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non-small-cell lung cancer in New Zealand. Intern Med J. 2020;50(6):716–725. doi: 10.1111/imj.14435
   PubMed Web of Science ®Google Scholar
• Cognigni V, Pecci F, Lupi A, et al. The landscape of ALK-Rearranged non-small cell lung cancer: a comprehensive review of clinicopathologic, genomic characteristics, and therapeutic perspectives. Cancers (Basel). 2022;14(19):4765. doi: 10.3390/cancers14194765
   PubMed Web of Science ®Google Scholar
• Ou SI, Zhu VW, Nagasaka M. Catalog of 5’ fusion partners in ALK-positive NSCLC circa 2020. JTO Clin Res Rep. 2020;1(1):100015. doi:10.1016/j.jtocrr.2020.100015
   PubMedGoogle Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394. doi: 10.1056/NEJMoa1214886
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-Positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–838. doi: 10.1056/NEJMoa1704795
   PubMed Web of Science ®Google Scholar
• Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019;7(5):437–446. doi: 10.1016/S2213-2600(19)30053-0
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim TM, Crino L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(7):874–886. doi: 10.1016/S1470-2045(17)30339-X
   PubMed Web of Science ®Google Scholar
• Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-Positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. J Clin Oncol. 2020;38(31):3592–3603. doi: 10.1200/JCO.20.00505
   PubMed Web of Science ®Google Scholar
• Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-Positive lung cancer. N Engl J Med. 2020;383(21):2018–2029. doi: 10.1056/NEJMoa2027187
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–4253. doi: 10.1200/JCO.2009.22.6993
   PubMed Web of Science ®Google Scholar
• Chia PL, Mitchell P, Dobrovic A, et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol. 2014;6:423–432. doi: 10.2147/CLEP.S69718
   PubMed Web of Science ®Google Scholar
• Du X, Shao Y, Qin HF, et al. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer. 2018;9(4):423–430. doi: 10.1111/1759-7714.12613
   PubMed Web of Science ®Google Scholar
• Rosas G, Ruiz R, Araujo JM, et al. ALK rearrangements: biology, detection and opportunities of therapy in non-small cell lung cancer. Crit Rev Oncol Hematol. 2019;136:48–55. doi: 10.1016/j.critrevonc.2019.02.006
   PubMed Web of Science ®Google Scholar
• Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25(15):4691–4700. doi: 10.1158/1078-0432.CCR-19-0624
   PubMed Web of Science ®Google Scholar
• Rolfo C, Cardona AF, Cristofanilli M, et al. Challenges and opportunities of cfDNA analysis implementation in clinical practice: perspective of the International Society of liquid biopsy (ISLB). Crit Rev Oncol Hematol. 2020;151:102978. doi: 10.1016/j.critrevonc.2020.102978
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177. doi: 10.1056/NEJMoa1408440
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119–1128. doi: 10.1016/S1470-2045(14)70362-6
   PubMed Web of Science ®Google Scholar
• Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-Rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol. 2016;34(7):661–668. doi: 10.1200/JCO.2015.63.9443
   PubMed Web of Science ®Google Scholar
• Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17(2):234–242. doi: 10.1016/S1470-2045(15)00488-X
   PubMed Web of Science ®Google Scholar
• Novello S, Mazieres J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409–1416. doi: 10.1093/annonc/mdy121
   PubMed Web of Science ®Google Scholar
• Crino L, Ahn MJ, De Marinis F, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-Rearranged non-small-cell lung cancer Previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol. 2016;34(24):2866–2873. doi: 10.1200/JCO.2015.65.5936
   PubMed Web of Science ®Google Scholar
• Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(22):2490–2498. doi: 10.1200/JCO.2016.71.5904
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–1667. doi: 10.1016/S1470-2045(18)30649-1
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Hida T, Nokihara H, et al. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2020;139:195–199. doi: 10.1016/j.lungcan.2019.11.025
   PubMed Web of Science ®Google Scholar
• Hotta K, Hida T, Nokihara H, et al. Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naive Japanese patients with ALK-positive non-small-cell lung cancer. ESMO Open. 2022;7(4):100527. doi: 10.1016/j.esmoop.2022.100527
   PubMedGoogle Scholar
• Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK-Positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027–2039. doi: 10.1056/NEJMoa1810171
   PubMed Web of Science ®Google Scholar
• Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-Positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16(12):2091–2108. doi: 10.1016/j.jtho.2021.07.035
   PubMed Web of Science ®Google Scholar
• Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917–929. doi: 10.1016/S0140-6736(17)30123-X
   PubMed Web of Science ®Google Scholar
• Pan Y, Deng C, Qiu Z, et al. The resistance mechanisms and treatment strategies for ALK-Rearranged non-small cell lung cancer. Front Oncol. 2021;11:713530. doi: 10.3389/fonc.2021.713530
   PubMed Web of Science ®Google Scholar
• Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-Rearranged lung cancer. Cancer Discov. 2016;6(10):1118–1133. doi: 10.1158/2159-8290.CD-16-0596
   PubMed Web of Science ®Google Scholar
• Haratake N, Toyokawa G, Seto T, et al. The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance. Expert Rev Anticancer Ther. 2021;21(9):975–988. doi: 10.1080/14737140.2021.1940964
   PubMed Web of Science ®Google Scholar
• Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-Positive lung cancer. Cancer Discov. 2018;8(6):714–729. doi: 10.1158/2159-8290.CD-17-1256
   PubMed Web of Science ®Google Scholar
• Kim S, Kim TM, Kim DW, et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol. 2013;8(4):415–422. doi: 10.1097/JTO.0b013e318283dcc0
   PubMed Web of Science ®Google Scholar
• Ai X, Niu X, Chang L, et al. Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient. Lung Cancer. 2018;123:83–86. doi: 10.1016/j.lungcan.2018.07.004
   PubMed Web of Science ®Google Scholar
• Yanagitani N, Uchibori K, Koike S, et al. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. Cancer Sci. 2020;111(3):932–939. doi: 10.1111/cas.14314
   PubMed Web of Science ®Google Scholar
• Dehghanian F, Kay M, Vallian S. F1174V mutation alters the ALK active conformation in response to crizotinib in NSCLC: insight from molecular simulations. J Mol Graph Model. 2017;75:287–293. doi: 10.1016/j.jmgm.2017.06.010
   PubMed Web of Science ®Google Scholar
• Elshatlawy M, Sampson J, Clarke K, et al. EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries. Mol Oncol. 2023;17(6):950–963. doi:10.1002/1878-0261.13446
   PubMed Web of Science ®Google Scholar
• Zhu VW, Cui JJ, Fernandez-Rocha M, et al. Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib. Lung Cancer. 2017;110:32–34. doi: 10.1016/j.lungcan.2017.05.018
   PubMed Web of Science ®Google Scholar
• Mehlman C, Chaabane N, Lacave R, et al. Ceritinib ALK T1151R resistance mutation in lung cancer with initial response to brigatinib. J Thorac Oncol. 2019;14(5):e95–e96. doi: 10.1016/j.jtho.2018.12.036
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Rooney M, Lin JJ, et al. Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity. Clin Cancer Res. 2019;25(22):6662–6670. doi: 10.1158/1078-0432.CCR-19-1436
   PubMed Web of Science ®Google Scholar
• Sabari JK, Santini FC, Schram AM, et al. The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers. Onco Targets Ther. 2017;10:1983–1992. doi: 10.2147/OTT.S109295
   PubMed Web of Science ®Google Scholar
• Recondo G, Mezquita L, Facchinetti F, et al. Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-Rearranged lung cancer. Clin Cancer Res. 2020;26(1):242–255. doi: 10.1158/1078-0432.CCR-19-1104
   PubMed Web of Science ®Google Scholar
• Hua G, Zhang X, Zhang M, et al. Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients. ESMO Open. 2022;7(1):100337. doi: 10.1016/j.esmoop.2021.100337
   PubMed Web of Science ®Google Scholar
• Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011;71(18):6051–6060. doi: 10.1158/0008-5472.CAN-11-1340
   PubMed Web of Science ®Google Scholar
• Miyawaki M, Yasuda H, Tani T, et al. Overcoming EGFR bypass signal-induced acquired resistance to ALK tyrosine kinase inhibitors in ALK-Translocated lung cancer. Mol Cancer Res. 2017;15(1):106–114. doi: 10.1158/1541-7786.MCR-16-0211
   PubMed Web of Science ®Google Scholar
• Lovly CM, McDonald NT, Chen H, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med. 2014;20(9):1027–1034. doi: 10.1038/nm.3667
   PubMed Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012;4(120):120ra117. doi: 10.1126/scitranslmed.3003316
   Web of Science ®Google Scholar
• Tanizaki J, Okamoto I, Okabe T, et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res. 2012;18(22):6219–6226. doi: 10.1158/1078-0432.CCR-12-0392
   PubMed Web of Science ®Google Scholar
• Tsuji T, Ozasa H, Aoki W, et al. Alectinib resistance in ALK-Rearranged lung cancer by dual salvage signaling in a clinically paired resistance model. Mol Cancer Res. 2019;17(1):212–224. doi: 10.1158/1541-7786.MCR-18-0325
   PubMed Web of Science ®Google Scholar
• Shi R, Filho SNM, Li M, et al. BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. Lung Cancer. 2020;146:78–85. doi: 10.1016/j.lungcan.2020.05.018
   PubMed Web of Science ®Google Scholar
• Gouji T, Takashi S, Mitsuhiro T, et al. Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor? J Thorac Oncol. 2014;9(3):e27–28. doi: 10.1097/JTO.0000000000000113
   PubMed Web of Science ®Google Scholar
• Ji J, Mitra A, Camidge DR, et al. Early alectinib resistance from MET amplification in ALK-Rearranged NSCLC: response to crizotinib with re-response to alectinib and crizotinib. Clin Lung Cancer. 2021;22(6):e851–e855. doi: 10.1016/j.cllc.2021.04.008
   PubMed Web of Science ®Google Scholar
• Yu Y, Ou Q, Wu X, et al. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer. Lung Cancer. 2019;127:19–24. doi: 10.1016/j.lungcan.2018.11.024
   PubMed Web of Science ®Google Scholar
• Dardaei L, Wang HQ, Singh M, et al. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med. 2018;24(4):512–517. doi: 10.1038/nm.4497
   PubMed Web of Science ®Google Scholar
• Zhu YC, Liao XH, Wang WX, et al. Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report. Onco Targets Ther. 2017;10:3187–3192. doi: 10.2147/OTT.S139718
   PubMed Web of Science ®Google Scholar
• Oya Y, Yoshida T, Uemura T, et al. Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: a case report. Oncol Lett. 2018;16(4):4219–4222. doi: 10.3892/ol.2018.9158
   PubMed Web of Science ®Google Scholar
• Yamagata A, Yokoyama T, Fukuda Y, et al. Alectinib re-challenge in small cell lung cancer transformation after chemotherapy failure in a patient with ALK-positive lung cancer: a case report. Respir Med Case Rep. 2021;33:101440. doi: 10.1016/j.rmcr.2021.101440
   PubMed Web of Science ®Google Scholar
• Park S, Han J, Sun JM. Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor. Lung Cancer. 2019;127:66–68. doi: 10.1016/j.lungcan.2018.11.027
   PubMed Web of Science ®Google Scholar
• Gong J, Gregg JP, Ma W, et al. Squamous cell transformation of primary lung adenocarcinoma in a patient with EML4-ALK fusion variant 5 refractory to ALK inhibitors. J Natl Compr Canc Netw. 2019;17(4):297–301. doi: 10.6004/jnccn.2019.7291
   PubMed Web of Science ®Google Scholar
• Kaiho T, Nakajima T, Iwasawa S, et al. ALK rearrangement adenocarcinoma with histological transformation to squamous cell Carcinoma resistant to alectinib and Ceritinib. Onco Targets Ther. 2020;13:1557–1560. doi: 10.2147/OTT.S236706
   PubMed Web of Science ®Google Scholar
• Wei J, van der Wekken AJ, Saber A, et al. Mutations in EMT-Related genes in ALK positive crizotinib resistant non-small cell lung Cancers. Cancers (Basel). 2018;10(1):10. doi: 10.3390/cancers10010010
   PubMed Web of Science ®Google Scholar
• Hida T, Seto T, Horinouchi H, et al. Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9. Cancer Sci. 2018;109(9):2863–2872. doi: 10.1111/cas.13721
   PubMed Web of Science ®Google Scholar
• Ou SI, Nishio M, Ahn MJ, et al. Efficacy of brigatinib in patients with advanced ALK-Positive NSCLC who progressed on alectinib or ceritinib: ALK in lung cancer trial of brigAtinib-2 (ALTA-2). J Thorac Oncol. 2022;17(12):1404–1414. doi: 10.1016/j.jtho.2022.08.018
   PubMed Web of Science ®Google Scholar
• Lin JJ, Zhu VW, Schoenfeld AJ, et al. Brigatinib in patients with alectinib-refractory ALK-Positive NSCLC. J Thorac Oncol. 2018;13(10):1530–1538. doi: 10.1016/j.jtho.2018.06.005
   PubMed Web of Science ®Google Scholar
• Song L, Xu Q, Lizaso A, et al. Brigatinib after progression from alectinib or crizotinib: paving the way for treatment sequencing of ALK inhibitors in ALK-Positive NSCLC. J Thorac Oncol. 2021;16(3):349–351. doi: 10.1016/j.jtho.2020.11.023
   PubMed Web of Science ®Google Scholar
• Urbanska EM, Sorensen JB, Santoni-Rugiu E. Efficacy of brigatinib after progression on alectinib or ceritinib: does one drug work in a pretreated heterogeneous ALK-Positive NSCLC population? J Thorac Oncol. 2023;18(3):e28–e29. doi: 10.1016/j.jtho.2022.11.028
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Doebele RC, Wang X, et al. Preliminary clinical and molecular analysis results from a single-arm phase 2 trial of brigatinib in patients with disease progression after next-generation ALK tyrosine kinase inhibitors in advanced ALK+ NSCLC. J Thorac Oncol. 2021;16(1):156–161. doi: 10.1016/j.jtho.2020.09.018
   PubMed Web of Science ®Google Scholar
• Nishio M, Yoshida T, Kumagai T, et al. Brigatinib in Japanese patients with ALK-Positive NSCLC Previously treated with alectinib and other tyrosine kinase inhibitors: outcomes of the phase 2 J-ALTA trial. J Thorac Oncol. 2021;16(3):452–463. doi: 10.1016/j.jtho.2020.11.004
   PubMed Web of Science ®Google Scholar
• Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28(1):70–81. doi: 10.1016/j.ccell.2015.05.010
   PubMed Web of Science ®Google Scholar
• Felip E, Shaw AT, Bearz A, et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021;32(5):620–630. doi: 10.1016/j.annonc.2021.02.012
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon BJ, Besse B, et al. ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J Clin Oncol. 2019;37(16):1370–1379. doi: 10.1200/JCO.18.02236
   PubMed Web of Science ®Google Scholar
• Frost N, Christopoulos P, Kauffmann-Guerrero D, et al. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Ther Adv Med Oncol. 2021;13:1758835920980558. doi: 10.1177/1758835920980558
   Web of Science ®Google Scholar
• Kron A, Alidousty C, Scheffler M, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29(10):2068–2075. doi: 10.1093/annonc/mdy333
   PubMed Web of Science ®Google Scholar
• Bearz A, Martini JF, Jassem J, et al. Efficacy of lorlatinib in treatment-naive patients with ALK-Positive advanced NSCLC in relation to EML4: ALK variant type and ALK with or without TP53 mutations. J Thorac Oncol. 2023. doi: 10.1016/j.jtho.2023.07.023.
   Google Scholar
• Lin JJ, Schoenfeld AJ, Zhu VW, et al. Efficacy of platinum/pemetrexed combination chemotherapy in ALK-Positive NSCLC refractory to second-generation ALK inhibitors. J Thorac Oncol. 2020;15(2):258–265. doi: 10.1016/j.jtho.2019.10.014
   PubMed Web of Science ®Google Scholar
• Takeyasu Y, Yoshida T, Masuda K, et al. Lorlatinib versus pemetrexed-based chemotherapy in patients with ALK-rearranged NSCLC Previously treated with alectinib. JTO Clin Res Rep. 2022;3(5):100311. doi: 10.1016/j.jtocrr.2022.100311
   PubMedGoogle Scholar
• Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22(18):4585–4593. doi: 10.1158/1078-0432.CCR-15-3101
   PubMed Web of Science ®Google Scholar
• Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321–1328. doi: 10.1093/annonc/mdz167
   PubMed Web of Science ®Google Scholar
• Patel SP, Pakkala S, Pennell NA, et al. Phase ib study of crizotinib plus pembrolizumab in patients with Previously untreated advanced non-small cell lung cancer with ALK translocation. Oncology. 2020;25(7):562–e1012. doi: 10.1634/theoncologist.2020-0034
   Google Scholar
• Felip E, de Braud FG, Maur M, et al. Ceritinib plus nivolumab in patients with advanced ALK-Rearranged non-small cell lung cancer: results of an open-label, multicenter, phase 1B study. J Thorac Oncol. 2020;15(3):392–403. doi: 10.1016/j.jtho.2019.10.006
   PubMed Web of Science ®Google Scholar
• Spigel DR, Reynolds C, Waterhouse D, et al. Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation - positive advanced non-small cell lung cancer (CheckMate 370). J Thorac Oncol. 2018;13(5):682–688. doi: 10.1016/j.jtho.2018.02.022
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. doi: 10.1056/NEJMoa1716948
   PubMed Web of Science ®Google Scholar
• Schenk EL. Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer-current status and future directions. Transl Lung Cancer Res. 2023;12(2):322–336. doi: 10.21037/tlcr-22-883
   PubMed Web of Science ®Google Scholar
• Ou SI, Nagasaka M, Brazel D, et al. Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC? Transl Oncol. 2021;14(11):101191. doi: 10.1016/j.tranon.2021.101191
   PubMed Web of Science ®Google Scholar
• Murray BW, Zhai D, Deng W, et al. TPX-0131, a potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations. Mol Cancer Ther. 2021;20(9):1499–1507. doi: 10.1158/1535-7163.MCT-21-0221
   PubMed Web of Science ®Google Scholar
• Hrustanovic G, Olivas V, Pazarentzos E, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015;21(9):1038–1047. doi: 10.1038/nm.3930
   PubMed Web of Science ®Google Scholar
• Desai A, Lovly CM. Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review. Transl Lung Cancer Res. 2023;12(3):615–628. doi: 10.21037/tlcr-22-708
   PubMed Web of Science ®Google Scholar
• Camidge DR, Barlesi F, Goldman JW, et al. Phase ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-met protein-expressing non-small-cell lung cancer. J Clin Oncol. 2023;41(5):1105–1115. doi: 10.1200/JCO.22.00739
   PubMed Web of Science ®Google Scholar
• Watanabe S, Sakai K, Matsumoto N, et al. Phase II trial of the combination of alectinib with Bevacizumab in alectinib refractory ALK-Positive nonsquamous non-small-cell lung cancer (NLCTG1501). Cancers (Basel). 2022;15(1):204. doi: 10.3390/cancers15010204
   PubMed Web of Science ®Google Scholar
• Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics. 2019;13(1):34. doi: 10.1186/s40246-019-0220-8
   PubMed Web of Science ®Google Scholar
• Lin YT, Chiang CL, Hung JY, et al. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. Eur J Cancer. 2021;156:1–11. doi: 10.1016/j.ejca.2021.06.043
   PubMed Web of Science ®Google Scholar
• Spagnuolo A, Maione P, Gridelli C. Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors. Expert Opin Emerg Drugs. 2018;23(3):231–241. doi: 10.1080/14728214.2018.1527902
   PubMed Web of Science ®Google Scholar
• Tiotiu A, Billon Y, Vaillant P, et al. Therapeutic strategies in advanced ALK positive non-small cell lung cancer. Rev Mal Respir. 2019;36(10):1107–1116. doi: 10.1016/j.rmr.2019.02.008
   PubMed Web of Science ®Google Scholar
• Esagian SM, Grigoriadou G, Nikas IP, et al. Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review. J Cancer Res Clin Oncol. 2020;146(8):2051–2066. doi: 10.1007/s00432-020-03267-x
   PubMed Web of Science ®Google Scholar
• Mezquita L, Swalduz A, Jovelet C, et al. Clinical relevance of an amplicon-based liquid biopsy for detecting ALK and ROS1 fusion and resistance mutations in patients with non–small-Cell lung cancer. JCO Precis Oncol. 2020;4(4):272–282. doi: 10.1200/PO.19.00281
   Google Scholar